Last update Aug. 24, 2022
Very Low Risk
Coagulation factor IX is a plasma glycoprotein consisting of 415 amino acids that is used to treat hemophilia B (Christmas disease, factor IX deficiency). It can be obtained from human plasma or produced by recombinant DNA technology (albutrepenonacog alfa, eftrenonacog alfa), as glycosylated forms (Nonacog alpha or gamma), or as a pegylated derivative (nonacog beta pegol). Intravenous administration.
Since the last update we have not found published data on its excretion in breastmilk.
Its very high molecular weigh make it highly unlikely that significant quantities will pass into breast milk.
Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant, except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.
Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs: compatible with Breastfeeding. (WHO 2002)
We do not have alternatives for B02BD04 since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM